Steel & Tube FY26 slides: revenue up 14%, but $61m loss on impairments

Steel & Tube’s FY26 revenue rose 13.9% to $438.9m and normalized EBITDA surged 376% to $9.9m, but the company posted a statutory net loss after tax of $61.2m due to $51.9m of impairment charges. Operating cash flow improved to $12.7m (+22% YoY) and product margins expanded 2.6ppt to 30.7%, yet net debt increased to $48m (from $36.3m) and dividends were placed on hold amid paused M&A and restricted capex (~$7m). Management flagged FY27 recovery potential as uncertain (“timing and pace remains uncertain”) with portfolio exits and further cost savings (annualized benefits locked at $3m), while noting macro disruption from the Middle East conflict and inflationary pressures.

Analysis

The equity is behaving like a recovery option, not a steady compounder: the impairment mostly resets the optics, but the real market variable is whether management can convert a leaner cost base into sustained cash generation before the cycle rolls over again. The important second-order signal is that the company is deliberately shrinking low-return activity and inventory intensity, which should improve working capital and pricing discipline across the channel, but it also implies less tolerance for volume volatility from smaller customers and suppliers.

The biggest risk is duration. If domestic demand stays soft for another 2-3 quarters, the balance sheet will still look serviceable on paper but the market will keep applying a distress discount because leverage is being carried by an earnings stream that is still cyclical and not yet proven post-reset. The bank extension buys time, not immunity; the equity will likely re-rate only when investors can see a sustained positive EBITDA run-rate plus evidence that the exit program is actually turning into cash rather than just accounting charges.

Consensus is probably overweighting the headline loss and underweighting the operating leverage embedded in a cleaner portfolio. That said, the market may be underestimating how much competitive intensity remains in commodity product lines: if pricing discipline slips or low-value volume has to be chased back, the margin recovery can flatten fast. The more interesting view is that the stock is cheap only if the recovery is real; if it is not, the residual equity value is mostly a claim on time, not on growth.

Key Decisions for Investors

• No immediate directional trade in SECI/STU; treat it as a high-beta recovery watchlist name rather than a clean long until there is evidence of sustained positive operating cash flow and lower leverage.
• Set a buy trigger only if the next update shows normalized EBITDA running at a clearly positive annualized rate and net debt/EBITDA trending down; use a starter long on a pullback into the NZ$0.40 area only if liquidity and bank covenant commentary stay stable.
• Do not short SECI/STU just because of the statutory loss; the impairment is backward-looking. If expressing downside, use a basket short against NZ domestic cyclicals rather than a standalone single-name short.
• Falsifier for a constructive view: if inventory rebuilds, operating cash flow turns negative, or management delays the planned exits/lease rationalization, abandon the recovery thesis quickly.
• Watch for a broader NZ construction/recovery trade only after rate cuts or infrastructure award flow improves; until then, the best risk/reward is staying patient rather than forcing a position.